Dosing Complete in Phase 1/2 1st Group of NTLA-2002 Trial for HAE
Intellia Therapeutics has completed dosing the first group of patients enrolled in a Phase 1/2 clinical trial testing its gene-editing therapy, NTLA-2002, for the treatment of hereditary angioedema (HAE). In the Phase 1 part of the study (NCT05120830), patients will receive a single infusion of NTLA-2002, delivered into…